Newron Pharmaceuticals SpA (NWRN)

Switzerland
1.73
+0.03(+1.76%)
  • Volume:
    24,073
  • Bid/Ask:
    1.70/1.79
  • Day's Range:
    1.70 - 1.75
  • Type:Equity
  • Market:Switzerland
  • ISIN:IT0004147952
  • S/N:2791431

NWRN Overview

Prev. Close
1.7
Day's Range
1.7-1.75
Revenue
5.63M
Open
1.7
52 wk Range
1.7-3.07
EPS
-1.14
Volume
24,073
Market Cap
30.87M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
18,579
P/E Ratio
-
Beta
1.57
1-Year Change
-20.28%
Shares Outstanding
17,845,345
Next Earnings Date
-
What is your sentiment on Newron Pharmaceuticals SpA?
or
Market is currently closed. Voting is open during market hours.

Newron Pharmaceuticals SpA Company Profile

Employees
23

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson’s disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralSellSellStrong Sell
Technical IndicatorsBuyBuySellStrong SellStrong Sell
SummaryNeutralNeutralSellStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.